AMGN•benzinga•
Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress
Summary
Wedbush initiates coverage on Zenas BioPharma, citing strong potential for obexelimab in autoimmune diseases, with key clinical data expected in 2025 and 2026.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 20, 2025 by benzinga